SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: JOHN W. who wrote (899)7/9/1997 12:35:00 AM
From: David S.   of 6136
 
"Dr. Amy Patick of Agouron, 39% of patients (25/64) who failed protease inhibitors responded to treatment with Viracept." Doctor Dave says...define respond.
Actually, by posting this note from Silverman, you have provided the opportunity for people who do not get paid by Agouron or do not have to recommend the stock in order to win corporate finance business to dissect the piece. Thank you.
PS - You might want to pick up the June issue of Individual Investor - it's got a red cover. AGPH has a huge ad which by the way, violates FDA guidelines. The ad is full of basic ca-ca or is it ka-ka? Please get the magazine, read the ad. If a drug is so good, why would that ad be necessary. In it, AGPH claims that Viracept can halt replication of the virus. We all know that this is an unproven medical claim, clearly crap - do these charletans think they're selling dish soap?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News